Literature DB >> 30711650

Lung Adenocarcinoma Harboring EGFR 19del/C797S/T790M Triple Mutations Responds to Brigatinib and Anti-EGFR Antibody Combination Therapy.

Xiaofei Wang1, Ling Zhou1, Jiani C Yin2, Xue Wu3, Yang W Shao4, Beili Gao5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30711650     DOI： 10.1016/j.jtho.2019.01.015

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  13 in total

Review 1.  The next tier of EGFR resistance mutations in lung cancer.

Authors:  Hannah L Tumbrink; Alena Heimsoeth; Martin L Sos
Journal:  Oncogene       Date:  2020-10-15       Impact factor: 9.867

Review 2.  New Strategies and Novel Combinations in EGFR TKI-Resistant Non-small Cell Lung Cancer.

Authors:  Nicolas Girard
Journal:  Curr Treat Options Oncol       Date:  2022-10-15

Review 3.  Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management.

Authors:  Alissa J Cooper; Lecia V Sequist; Jessica J Lin
Journal:  Nat Rev Clin Oncol       Date:  2022-05-09       Impact factor: 65.011

4.  Two case reports of non-small cell lung cancer patients harboring acquired EGFR T790M-cis-C797S benefit from immune checkpoint inhibitor combined with platinum-based doublet chemotherapy.

Authors:  Zizheng Song; Guanying Ren; Ling Hu; Xiaolei Wang; Jin Song; Youchao Jia; Guofa Zhao; Aimin Zang; Haiwei Du; Ying Sun; Xiaopeng Zhao
Journal:  Ann Transl Med       Date:  2022-06

5.  Patterns and Treatment Strategies of Osimertinib Resistance in T790M-Positive Non-Small Cell Lung Cancer: A Pooled Analysis.

Authors:  Chunsheng Wang; Kewei Zhao; Shanliang Hu; Minghuan Li; Yipeng Song
Journal:  Front Oncol       Date:  2021-03-02       Impact factor: 6.244

6.  Possibility of brigatinib-based therapy, or chemotherapy plus anti-angiogenic treatment after resistance of osimertinib harboring EGFR T790M-cis-C797S mutations in lung adenocarcinoma patients.

Authors:  Yaning Yang; Haiyan Xu; Li Ma; Lu Yang; Guangjian Yang; Shuyang Zhang; Xin Ai; Shucai Zhang; Yan Wang
Journal:  Cancer Med       Date:  2021-10-06       Impact factor: 4.452

7.  Structure-based classification predicts drug response in EGFR-mutant NSCLC.

Authors:  Jacqulyne P Robichaux; Xiuning Le; R S K Vijayan; J Kevin Hicks; Simon Heeke; Yasir Y Elamin; Heather Y Lin; Hibiki Udagawa; Ferdinandos Skoulidis; Hai Tran; Susan Varghese; Junqin He; Fahao Zhang; Monique B Nilsson; Lemei Hu; Alissa Poteete; Waree Rinsurongkawong; Xiaoshan Zhang; Chenghui Ren; Xiaoke Liu; Lingzhi Hong; Jianjun Zhang; Lixia Diao; Russell Madison; Alexa B Schrock; Jennifer Saam; Victoria Raymond; Bingliang Fang; Jing Wang; Min Jin Ha; Jason B Cross; Jhanelle E Gray; John V Heymach
Journal:  Nature       Date:  2021-09-15       Impact factor: 69.504

Review 8.  "Sandwich" Strategy to Intensify EGFR Blockade by Concurrent Tyrosine Kinase Inhibitor and Monoclonal Antibody Treatment in Highly Selected Patients.

Authors:  Guoqing Zhang; Beibei Yan; Yanan Guo; Hang Yang; Jindong Li
Journal:  Front Oncol       Date:  2022-07-08       Impact factor: 5.738

Review 9.  Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer.

Authors:  Alessandro Leonetti; Sugandhi Sharma; Roberta Minari; Paola Perego; Elisa Giovannetti; Marcello Tiseo
Journal:  Br J Cancer       Date:  2019-09-30       Impact factor: 7.640

10.  Growth Suppression in Lung Cancer Cells Harboring EGFR-C797S Mutation by Quercetin.

Authors:  Kuo-Yen Huang; Tong-Hong Wang; Chin-Chuan Chen; Yann-Lii Leu; Hsin-Jung Li; Cai-Ling Jhong; Chi-Yuan Chen
Journal:  Biomolecules       Date:  2021-08-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.